Vertex Pharmaceuticals (VRTX) grants 8,251 RSUs to EVP Ourania Tatsis

Rhea-AI Filing Summary

Vertex Pharmaceuticals reported a compensation-related equity grant to EVP and Chief Regulatory & Quality Officer Ourania Tatsis. She acquired 8,251 shares of common stock in the form of a restricted stock unit award on 07/21/2026, vesting on 03/31/2030, bringing her direct holdings to 53,572 shares.

Insider Trade Summary

Net Buyer: 8,251 shares

Net Buy 1 txn

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	8,251	$0.00	$0.00

Holdings After Transaction: Common Stock — 53,572 shares (Direct)

Footnotes (1)

1. F1. Restricted stock unit award that vests on 03/31/2030.

Key Figures

RSU award shares: 8,251 shares Holdings after transaction: 53,572 shares Vesting date: 03/31/2030

3 metrics

RSU award shares 8,251 shares Restricted stock unit grant on 07/21/2026

Holdings after transaction 53,572 shares Direct common stock holdings following the award

Vesting date 03/31/2030 Scheduled vesting of the restricted stock unit award

Key Terms

Restricted stock unit award, EVP, Chief Reg. & Quality Off., Common Stock

3 terms

Restricted stock unit award financial

"Restricted stock unit award that vests on 03/31/2030."

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

EVP, Chief Reg. & Quality Off. other

"Officer title listed as EVP, Chief Reg. & Quality Off."

Common Stock financial

"Security title for the reported transaction is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/24/2026 - 04:16 AM Accepted by SEC EDGAR 07/24/2026 - 04:15 AM Learn about SEC filing dates

FAQ

What equity award did Vertex (VRTX) grant to EVP Ourania Tatsis?

EVP Ourania Tatsis received a restricted stock unit award of 8,251 shares of Vertex common stock on 07/21/2026. The units vest on 03/31/2030, representing a long-term, time-based compensation grant.

How did the reported RSU grant affect Ourania Tatsis’s VRTX shareholdings?

After the grant, Ourania Tatsis directly holds 53,572 shares of Vertex common stock. The 8,251-share award is included in this total and remains subject to vesting on 03/31/2030.

When do the new Vertex (VRTX) restricted stock units for Ourania Tatsis vest?

The restricted stock unit award to Ourania Tatsis vests on 03/31/2030. Until that vesting date, the 8,251 units remain subject to service or other conditions described in the award’s terms.

Was the Ourania Tatsis VRTX equity grant made under a Rule 10b5-1 trading plan?

The transaction is reported as a grant or award, and the Rule 10b5-1 checkbox is not marked as a plan transaction. This indicates it is a standard compensation grant rather than trading under a preset plan.

What type of VRTX security did Ourania Tatsis receive in this award?

The award consists of restricted stock units settled in Vertex common stock, totaling 8,251 shares. These RSUs convert into common shares upon vesting, scheduled for 03/31/2030.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2026		A		8,251(1)	A	$0	53,572	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award that vests on 03/31/2030.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)